AFP and hepatocellular carcinoma: In addition, we believe that there is significant potential for LC-SPIK to be combined with other biomarkers, such as AFP and PIVKA-II, other genomic biomarkers, or AI, to greatly improve clinical performance and significantly improve clinicians’ ability to detect and manage HCC.